Vol. 73, No. 22

LambdaSa1 and LambdaSa2 Prophage Lysins of *Streptococcus agalactiae*[▽]

David G. Pritchard,[1]* Shengli Dong,[1] Marion C. Kirk,[2] Robert T. Cartee,[3] and John R. Baker[1]

*Department of Biochemistry and Molecular Genetics,[1] Comprehensive Cancer Center,[2] and Department of Microbiology,[3]
University of Alabama at Birmingham, Birmingham, Alabama*

Putative *N*-acetylmuramyl-L-alanine amidase genes from LambdaSa1 and LambdaSa2 prophages of *Streptococcus agalactiae* were cloned and expressed in *Escherichia coli*. The purified enzymes lysed the cell walls of *Streptococcus agalactiae*, *Streptococcus pneumoniae*, and *Staphylococcus aureus*. The peptidoglycan digestion products in the cell wall lysates were not consistent with amidase activity. Instead, the structure of the muropeptide digestion fragments indicated that both the LambdaSa1 and LambdaSa2 lysins exhibited γ-D-glutaminyl-L-lysine endopeptidase activity. The endopeptidase cleavage specificity of the lysins was confirmed using a synthetic peptide substrate corresponding to a portion of the stem peptide and cross bridge of *Streptococcus agalactiae* peptidoglycan. The LambdaSa2 lysin also displayed β-D-*N*-acetylglucosaminidase activity.

Bacteriophages often lyse their bacterial hosts at the end of an infective cycle and release their progeny into the surrounding medium. Phages of gram-positive bacteria usually accomplish this by employing a two-component lytic system consisting of a holin and a lysin (11). The holin makes the bacterial cell membrane porous, thereby exposing the peptidoglycan layer of the cell wall to the degradative action of the lysin. Phage lysins and the related endogenous bacterial cell wall hydrolases that cleave many different bonds in peptidoglycan have been found (11, 12). They include β-D-*N*-acetylmuramidases, β-D-*N*-acetylglucosaminidases, lytic transglycosylases, *N*-acetylmuramyl–L-alanine amidases, and various endopeptidases that cleave either the stem peptide or cross bridge peptide of peptidoglycan (11, 12).

The observation that many phage lysins specifically lyse susceptible gram-positive bacteria which have been exposed to the enzyme externally has led to recent intense interest in using them as antimicrobial agents. For example, Nelson and coworkers showed that nasopharyngeal colonization of mice with *Streptococcus pyogenes* could be cleared using the C_1 phage lysin from a group C streptococcus (14). Schuch et al. reported that the phage enzyme PlyG killed vegetative cells of *Bacillus anthracis* and protected mice from an otherwise fatal intraperitoneal infection with *Bacillus cereus* (16). Similarly, Jado and coworkers showed that a single intraperitoneal injection of either of the pneumococcal phage lysins Pal, an amidase, and Dpl-1, a lysozyme, was sufficient to protect mice in a murine model of pneumococcal sepsis (7). These workers also demonstrated a synergistic effect on pneumococcal killing when the two enzymes were administered together. A similar synergism among different peptidoglycan cleavage activities may be why many phage lysins evolved with more than one type of lytic activity. The different peptidoglycan cleavage activities are usually located on distinct enzymatic domains, often along with one or more cell wall binding domains (11, 12). We recently described the cloning and elucidation of cleavage specificities of the B30 lysin from a bacteriophage of *Streptococcus agalactiae* (1, 15). It contains an endopeptidase domain, a glycosidase domain, and a putative SH3b cell wall binding domain (1, 15). The endopeptidase activity was shown to cleave between the D-alanine of the stem peptide and the L-alanine in the cross bridge, and the glycosidase had the specificity of an *N*-acetylmuramidase (1). We initially cloned the genes for the two lysins described in this report, expecting them to exhibit *N*-acetylmuramyl–L-alanine amidase activity; however, as described below, the characterization of their cleavage specificities showed that they were not amidases.

MATERIALS AND METHODS

Bacterial strains and culture conditions. *Streptococcus agalactiae* and *Staphylococcus aureus* strains from our collections were routinely plated on Trypticase soy agar (BBL) containing 5% sheep blood or cultured in Todd-Hewitt broth (Difco) at 37°C without shaking. *Streptococcus pneumoniae* was cultured in Todd-Hewitt broth containing 0.5% (wt/vol) yeast extract. Serotype V strain 2603 V/R of *Streptococcus agalactiae* was obtained from the ATCC (no. BAA-611). *Escherichia coli* strains INVαF′ and BL21(DE3) were routinely grown at 37°C with shaking in Luria-Bertani (LB) broth. However, for protein expression, cultures were grown at room temperature.

Cloning the genes for LambdaSa1 and LambdaSa2 lysins. Chromosomal DNA was prepared from group B streptococcus (GBS) strain 2603 V/R by a procedure described previously (9). Briefly, this involved digesting washed cells with mutanolysin at 60°C for 30 min, adding sodium dodecyl sulfate (2% final concentration) to lyse the cells, cooling the cells to 37°C and treating them with RNase, purifying the DNA by phenol-chloroform extraction, and finally precipitating the DNA with isopropanol. The two lysin genes were PCR amplified with chromosomal DNA as a template. The LambdaSa1 gene was amplified using the primers SAG0604F, 5′ GTA CAG TCC ATA TGG TAA TTA TAT TTG AGC AAG CTA TC 3′, and SAG0604R, 5′ CGT ACA TGC TCG AGC ATA TCT GTT GCA TCA ATT AAG TAA G 3′. The primers for the LambdaSa2 gene were SAG1837F, 5′ GTA CAG TCC ATA TGG AAA TCA ACA CTG AAA TAG CCA TTG 3′, and SAG1837R, 5′CGT ACA TGC TCG AGA AGT GGC TTT TTA GTC AGT TCA T 3′. The PCR products were cloned into the pGEM-T vector (Promega, Madison, WI) and transformed into *E. coli* strain INVαF′. Purified plasmid DNA was cleaved with the restriction endonucleases NdeI and XhoI, and the inserts were cloned into the similarly digested expression vector pET21a (Novagen). This construct was then transformed into *E. coli* strain BL21(DE3) for enzyme expression. The sequence of the resulting plasmid was confirmed by DNA sequencing.

Expression and purification of cloned lysins. Starter cultures of *E. coli* BL21(DE3) containing the recombinant plasmids were grown overnight in LB medium containing 50 μg/ml ampicillin at 37°C with shaking at 250 rpm. This

---

* Corresponding author. Mailing address: Department of Biochemistry & Molecular Genetics, MCLM 552, University of Alabama at Birmingham, 1530 3rd Ave. S., Birmingham, AL 35294-0005. Phone: (205) 934-6023. Fax: (205) 934-6022. E-mail: davidp1@uab.edu.

FIG. 1. (A) Domain structure of the cloned LambdaSa1 and LambdaSa2 lysins; (B) structure of the GBS peptidoglycan showing the glycosidic bond cleaved by LambdaSa2 lysin and the endopeptidase cleavage site for both lysins.

culture was diluted with 20 volumes of fresh medium (3 liters) and grown at 37°C until it reached mid-log phase (an optical density at 550 nm of 0.5). Lysin expression was induced by adding isopropyl-β-D-thiogalactopyranoside to give a final concentration of 1 mM. After growing for an additional 4.5 h at room temperature, the cells were harvested by centrifugation and washed three times with extraction buffer (50 mM NaH_2PO_4, 300 mM NaCl, 10 mM imidazole, pH 8.0). The pellet was resuspended in 100 ml of extraction buffer and sonicated in an ice bath for a total of 5 min at 60% of the maximum power using a model 300 Fisher Sonic Dismembrator. Cell debris was removed by centrifugation and the resulting supernatant passed over a 10-ml Ni-NTA affinity column (Qiagen), which was then washed and eluted according to the manufacturer's instructions. Imidazole was removed from the sample by passing it through a 2.5- by 14-cm column of Bio-Gel P4 run in 50 mM ammonium acetate, pH 6.8. Fractions with enzyme activity were pooled and concentrated by ultrafiltration to give final approximate concentrations of 10 mg/ml for LambdaSa1 lysin and 1 mg/ml for LambdaSa2 lysin.

Turbidity reduction assays were carried out on washed cells or bacterial cell walls essentially as we described previously (15). However, the buffer used was 50 mM ammonium acetate, pH 6.8. Bacterial cell walls were also prepared as described previously (15). Plate assays for lytic activity were performed in 1% agarose in the above-described buffer containing a suspension of cells or cell walls sufficient to make the layers turbid. Holes (5 mm) were punched in the layers, and 10-μl samples were added. After incubation at 37°C for several hours, or overnight, distinctive clear zones formed around sample wells containing lysin activity.

Lysin endopeptidase activity was estimated by measuring the free amino groups released during digestions. Cell walls were enzymatically digested as described above but with 50 mM sodium acetate substituting for the ammonium acetate. After centrifugation of the digests, aliquots of the supernatants were assayed for free amino groups by a spectrophotometric method employing picryl sulfonic acid (13). In order to determine the site of endopeptidase cleavage, a synthetic peptide corresponding to a portion of the stem peptide and cross bridge of the GBS peptidoglycan (Fig. 1) was lysin digested. The hexapeptide Ala–D-γ-Glu–Lys–D-Ala–Ala–Ala was custom synthesized by Genscript Corp. (Piscataway, NJ), and the two carboxyl groups of the peptide were amidated (8, 17) to yield Ala–D-γ-Gln–Lys–D-Ala–Ala–Ala–amide. The digestion products were characterized by mass spectrometry.

Sample preparation for mass spectrometry. Washed cell walls of different bacterial species were treated with purified lysins overnight. In some cases, double digests using both mutanolysin and a phage lysin were carried out. In all cases, the digestion mixtures were centrifuged, and the supernatants were passed through a centrifugal ultrafilter with a molecular weight cutoff of 5,000 (Ultrafree-MC centrifugal filter; Millipore Corp., Billerica, MA) prior to analysis in order to remove proteins and capsular polysaccharides. Alkaline de-O acetylation of glycopeptides was accomplished by treating samples with 5% triethylamine at room temperature for 30 min followed by evaporation to dryness in a vacuum centrifuge. Acetate released from glycopeptides was measured enzymatically using a kit supplied by R-Biopharm, Inc. (Marshall, MI).

Electrospray ionization mass spectrometry. Electrospray ionization mass spectrometry was performed on a Micromass Q-TOF2 mass spectrometer (Micromass Ltd., Manchester, United Kingdom). Samples were dissolved in either water or dilute ammonium acetate buffer. Sodium salts were avoided to minimize the formation of sodium adducts. Online injections were made into a stream of 50/50 acetonitrile-water containing 0.1% formic acid pumped at a rate of 1 μl/min. Negative ion mass spectra were obtained using a needle voltage of 2.8 kV. The mass spectral data were processed using the Max-Ent3 module of MassLynx 3.5.

Determining the mode of glycosidic cleavage. The mode of glycosidic cleavage was accomplished by identifying the amino sugar at the reducing terminus of glycopeptides obtained upon digestion with a lysin. Procedures for the borohydride reduction, propanolysis, re-N acetylation, and trimethylsilylation of samples have been described previously (1). Derivatized samples were analyzed on a gas-liquid chromatograph (GLC)-mass spectrometer (Varian 4000; Varian, Inc., Palo Alto, CA) fitted with a 30-m (0.25-mm-diameter) VF-5 capillary column. The column temperature was maintained at 100°C for 5 min, increased to 275°C at a rate of 20°C/min, and finally held at 275°C for 5 min. In an improved version of the original procedure used in this work, the column effluent was analyzed by chemical ionization mass spectrometry using acetonitrile as the reagent gas. This relatively gentle means of sample ionization results in little fragmentation and often yields ions that are highly characteristic of a particular sugar or alditol.

RESULTS AND DISCUSSION

The increasing incidence of antibiotic resistance in pathogenic bacteria has contributed to the recent interest in bacteriophage lysins as potential antimicrobial agents. Encouraging results from several animal experiments are likely to prompt further work directed toward using phage lysins to prevent or treat human bacterial diseases (1, 3, 6, 7, 10, 14, 16).

The sequencing of bacterial genomes often reveals the pres-

FIG. 2. Negative ion mass spectra of the low-molecular-weight products of lysin-digested bacterial cell walls. (A) LambdaSa2-digested GBS cell walls; (B) LambdaSa2-digested GBS cell walls treated with 5% (vol/vol) aqueous triethylamine; (C) LambdaSa1 plus mutanolysin-digested GBS cell walls; (D) LambdaSa2-digested *Staphylococcus aureus* cell walls; (E) LambdaSa2-digested *Streptococcus pneumoniae* cell walls. The 694.4 m/z fragment is due to a disaccharide dipeptide composed of *N*-acetylglucosamine, *N*-acetylmuramic acid, alanine, and glutamine. The 652.4 m/z fragment has one less acetyl group, and the 736.4 m/z fragment has one more acetyl group than the core glycopeptide (694.4).

FIG. 3. Possible structures of a disaccharide containing *N*-acetylglucosamine and *N*-acetylmuramic acid linked to Ala-Gln.

ence of prophage lysin genes. Such genes are usually identified by their sequence similarities to known lysin genes, and on this basis, they are generally annotated as coding for amidases, lysozymes, endopeptidases, or other types of lysins. Occasionally, lysin genes are annotated incorrectly. The sequenced genome of strain 2603 V/R of *S. agalactiae* contains several lysin genes, including those for two putative amidases from LambdaSa1 and LambdaSa2 prophages (19). These two lysin genes were cloned and expressed as described above. Crude cell lysates obtained by sonic disruption of the *E. coli* cells were found to rapidly lyse *S. agalactiae* cells and cell walls in a turbidity reduction assay and also to give distinct zones of clearing in the lysin plate assay (data not shown). Interestingly, although both LambdaSa1 and LambdaSa2 lysins gave slightly smaller clear zones in the agar plate than did the B30 lysin that we described previously, the zones showed complete clearing with no residual turbidity, unlike the B30 lysin. Presumably this is because some of the products of B30 digestion are large enough to remain insoluble. Since digestion of *S. agalactiae* cell

walls with affinity-purified LambdaSa1 or LambdaSa2 lysins led to a significant increase in free amino groups, it was evident that the lysins possessed either *N*-acetylmuramyl-L-alanine amidase or endopeptidase activities. Further characterization of the lysin digestion products was necessary to identify the type of enzymatic activity present.

Lysin digestion products of *S. agalactiae* cell walls that had been passed through an ultrafilter with a molecular weight cutoff of 5,000 were examined by electrospray mass spectrometry in the negative ion mode. No significant peaks above background were found in LambdaSa1 lysin digests. So although LambdaSa1 lysin rapidly decreases the turbidity of a suspension of *S. agalactiae* cell walls, it does not yield fragments small enough to pass through an ultrafilter with a molecular weight cutoff of 5,000. However, LambdaSa2 lysin digests contained low-molecular-weight products that gave remarkably simple mass spectra (Fig. 2A). Two prominent peaks, 694 m/z and 736 m/z, were observed. The first peak corresponds to the M − 1 ion of a disaccharide containing *N*-acetylglucosamine and *N*-acetylmuramic acid linked to Ala-Gln and will have the structure of compound I or II shown in Fig. 3.

The production of this glycopeptide indicates that both endopeptidase and glycosidase activities are present. The second peak at 736 m/z is 42 mass units higher than the first peak and appeared to be the same glycopeptide with an additional acetyl group. A brief alkaline treatment of the sample with aqueous triethylamine resulted in the loss of the 736 m/z peak (Fig. 2B), consistent with the presence of a labile O-linked acetyl group. Confirmation that acetate was released was obtained by enzymatic measurement of the released acetate (data not shown).

The presence of alanine and glutamine in the muropeptides is evidence that the lysin possesses an endopeptidase activity capable of cleaving between D-γ-glutamine and lysine in the stem peptide of the peptidoglycan. In order to support this finding, the peptide Ala–D-γ-Gln–Lys–D-Ala–Ala–Ala–amide was synthesized from Ala–D-γ-Glu–Lys–D-Ala–Ala–Ala as described in Materials and Methods. Digesting this peptide with LambdaSa2 lysin resulted in the nearly complete loss of the substrate peptide (M + 1 = 558) and the appearance of a peak at 339 m/z corresponding to the M + 1 ion of Lys–D-Ala–Ala–Ala–amide, confirming that it is the γ linkage between D-Gln and L-Lys that is cleaved by this lysin.

The amino acid sequence of LambdaSa2 lysin contains two domains, annotated as amidase-5 and amidase-4 (Fig. 1). In contrast, the smaller LambdaSa1 lysin lacks the amidase-4 domain, and its amidase-5 domain has 71% amino acid identity to that of the LambdaSa2 lysin. Since the digestion of cell walls with either lysin results in the exposure of free amino groups, it was predicted that the amidase-5 domain is responsible for endopeptidase activity in both cases. The observed glycosidase

activity of the LambdaSa2 lysin would then be expected to be associated with the amidase-4 domain. Since this domain is absent in the LambdaSa1 lysin, we predicted that double digestion of *S. agalactiae* cell walls with both LambdaSa1 lysin and the muramidase mutanolysin would yield glycopeptide II. As shown in Fig. 2C, the double digest gave the same two muropeptide fragments observed in LambdaSa2 digests. Therefore, the amidase-5 domain of the LambdaSa1 lysin is also responsible for peptidoglycan cleavage at its D-γ-Gln-Lys linkage.

LambdaSa1 and LambdaSa2 lysins also degrade the cell walls of *Staphylococcus aureus* and *S. pneumoniae*, but the relative proportions of the glycopeptides in LambdaSa2 digests vary. LambdaSa2 digests of *S. agalactiae* cell walls (Fig. 2A) contain approximately equal amounts of a glycopeptide composed of alanine, glutamine, *N*-acetylglucosamine and *N*-acetylmuramic acid (*m/z* 694), and a similar glycopeptide containing an additional acetyl group (*m/z* 736). However, as shown in Fig. 2D, LambdaSa2 digests of *Staphylococcus aureus* cell walls have a much higher proportion of an O-acetylated muropeptide (736 *m/z*). This O-acetylated glycopeptide was a minor component in digests of *S. pneumoniae* cell walls (Fig. 2E). These digests contained about equal amounts of the core disaccharide-dipeptide and an N-deacetylated form of the compound that gives a peak at 652 *m/z*. Acetylation of *S. aureus* cell walls occurs at the C-6–OH of the *N*-acetylmuramic acid residues and has been reported to render the cell walls resistant to lysozyme (2). Similarly, the N deacetylation of *N*-acetylglucosamine residues in *S. pneumoniae* peptidoglycan has also been shown to make the cell walls resistant to lysozyme (20). Clearly, the presence of O-acetylated and N-deacetylated glycopeptides in LambdaSa2 lysin digests show that LambdaSa2 lysin, unlike lysozyme, is capable of cleaving peptidoglycan with these two types of modifications.

In order to determine whether the glycosidase activity of LambdaSa2 lysin cleaves after an *N*-acetylmuramic acid or an *N*-acetylglucosamine residue, it was necessary to establish their sequence in the glycopeptide digestion products, i.e., whether the dual action of LambdaSa2's glycosidase and endopeptidase activities release glycopeptide I, II, or both. We were unable to confidently determine this by electrospray mass spectrometry alone. We, therefore, reduced the glycopeptides with sodium borohydride and identified the resulting amino sugar alditol by a GLC-mass spectrometry procedure. As described previously, depolymerization of the samples using propanolysis greatly improves the gas chromatographic separation of the amino sugars and alditols (1). In addition, the use of chemical ionization results in very limited fragmentation and yields high-molecular-mass ions that can selectively be monitored to identify the amino sugar or alditol. Unexpectedly, the mass spectra of the derivatized four sugars and alditols all possessed molecular ions, indicating that not only the hydroxyl groups but also the nitrogen of the acetamido groups had been trimethylsilylated (data not shown). Figure 4A shows the total ion chromatogram obtained for a mixture of GlcNAc, GlcNAc-ol (reduced GlcNAc), MurNAc, and MurNAc-ol (reduced MurNAc). Selected ion monitoring of the indicated fragment ions clearly distinguishes each sugar or alditol (Fig. 4B to E). Figure 4F shows the results obtained for LambdaSa2 lysin digestion products when the indicated four ions were monitored.


FIG. 4. Identification of the site of glycosidic bond cleavage by GLC-mass spectrometry. (A) Total ion chromatogram (TIC) of a mixture of derivatized *N*-acetylglucosamine, *N*-acetylglucosaminitol, *N*-acetylmuramic acid, and *N*-acetylmuramitol; (B to E) selected ion chromatograms of the same sample for *m/z* 584 (GlcNAC-ol) (B), *m/z* 552 (GlcNAc) (C), *m/z* 626 (MurNAc-ol) (D), and *m/z* 462 (MurNAc) (E) ions; (F) selected ion chromatogram for the four ions of *m/z* 462, 552, 584, and 626 for a LambdaSa2 digest of GBS cell walls; (G) selected ion chromatogram for the same four ions as those used for panel F for a double digest of GBS cell walls by LambdaSa1 and mutanolysin. SIM, selected ion monitoring.

Two main peaks corresponding to *N*-acetylglucosaminitol and *N*-acetylmuramic acid are present, showing that glycopeptide I was present and was the product of *N*-acetylglucosaminidase action. That is to say, the LambdaSa2 lysin possesses *N*-acetylglucosaminidase and not *N*-acetylmuramidase activity. A much smaller peak due to MurNAc-ol was also present in the chromatogram showing that some MurNAc residues were at the reducing termini of digestion fragments. However, as we pointed out previously, this is most likely because peptidoglycan chains are biosynthesized from lipid-linked glycopeptide precursor units (lipid II) that have MurNAc residues at their reducing termini, and the polysaccharide chains of the GBS peptidoglycan are short (1). Analysis of the double digest with LambdaSa1 lysin and mutanolysin revealed peaks due to *N*-acetylglucosamine and *N*-acetylmuramitol, indicating that glycopeptide II was present in this digest. This is consistent with the known *N*-acetylmuramidase activity of mutanolysin. Thus, it is concluded that the GBS prophage LambdaSa2 lysin possesses both *N*-acetylglucosaminidase and γ-D-glutaminyl–L-lysine endopeptidase activities. The smaller LambdaSa1 lysin possesses only the endopeptidase activity.

We previously described the cleavage specificities of the B30 phage lysin of *S. agalactiae* (1). We found that it possessed two enzymatic domains, an endopeptidase domain and an *N*-acetylmuramidase domain. Using synthetic peptide substrates mimicking the stem peptide and cross bridge peptide of GBS peptidoglycan, we showed that the endopeptidase specif-

ically cleaves between the D-Ala of the stem peptide and an L-Ala of the cross bridge. However, the endopeptidase activities of the two lysins described in this paper cleave the stem peptide between D-γ-glutamine and L-lysine. It is of interest, and possible significance, that the B30 lysin and both lysins described in the current study cleave after D-amino acid residues, i.e., at D-Ala–L-Ala or at D-γ-Gln–L-Lys. Cleavage of linkages involving a D-amino acid may help ensure that the endopeptidases target cell wall peptidoglycan and not protein components of the cell wall.

Lopez and Garcia pointed out that lysins typically possess both substrate binding and bond cleavage specificities (12). Cell wall binding domains of lysins are responsible for conferring substrate specificity, whereas the enzymatic domains determine which bonds of the peptidoglycan are cleaved. The putative cell wall binding domain of the LambdaSa1 lysin is an SH3b domain, while the two putative cell wall binding domains of the LambdaSa2 lysin are of the Cpl-7 type (Fig. 1A). We focused on the enzymatic domains, however, in the current study.

Chimeric lysins composed of enzymatic and cell wall binding domains from different sources have been constructed (4–6, 18). Some of these combinations have unique, potentially useful properties. For example, Donovan et al. recently fused the gene for lysostaphin to either the entire B30 lysin gene or just the endopeptidase domain of the B30 lysin. Expression of these constructs yielded chimeric enzymes that displayed lytic activity against all three major mastitis-causing pathogens of dairy cattle, *Streptococcus agalactiae* (GBS), *Streptococcus uberis*, and *Staphylococcus aureus* (6). Knowledge of the precise cleavage specificities of phage lysins, therefore, is important for the rational design of such engineered chimeric enzymes.

REFERENCES

1. **Baker, J. R., C. Liu, S. Dong, and D. G. Pritchard.** 2006. Endopeptidase and glycosidase activities of the bacteriophage B30 lysin. Appl. Environ. Microbiol. **72:**6825–6828.
2. **Bera, A., S. Herbert, A. Jakob, W. Vollmer, and F. Gotz.** 2005. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of *Staphylococcus aureus*. Mol. Microbiol. **55:**778–787.
3. **Cheng, Q., D. Nelson, S. Zhu, and V. A. Fischetti.** 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. **49:**111–117.
4. **Croux, C., C. Ronda, R. Lopez, and J. L. Garcia.** 1993. Interchange of functional domains switches enzyme specificity: construction of a chimeric pneumococcal-clostridial cell wall lytic enzyme. Mol. Microbiol. **9:**1019–1025.
5. **Diaz, E., R. Lopez, and J. L. Garcia.** 1991. Chimeric pneumococcal cell wall lytic enzymes reveal important physiological and evolutionary traits. J. Biol. Chem. **266:**5464–5471.
6. **Donovan, D. M., S. Dong, W. Garrett, G. M. Rousseau, S. Moineau, and D. G. Pritchard.** 2006. Peptidoglycan hydrolase fusions maintain their parental specificities. Appl. Environ. Microbiol. **72:**2988–2996.
7. **Jado, I., R. Lopez, E. Garcia, A. Fenoll, J. Casal, and P. Garcia.** 2003. Phage lytic enzymes as therapy for antibiotic-resistant *Streptococcus pneumoniae* infection in a murine sepsis model. J. Antimicrob. Chemother. **52:**967–973.
8. **Lewis, S. D., and J. A. Shafer.** 1973. Conversion of exposed aspartyl and glutamyl residues in proteins to asparaginyl and glutaminyl residues. Biochim. Biophys. Acta **303:**284–291.
9. **Lin, B., S. K. Hollingshead, J. E. Coligan, M. L. Egan, J. R. Baker, and D. G. Pritchard.** 1994. Cloning and expression of the gene for group B streptococcal hyaluronate lyase. J. Biol. Chem. **269:**30113–30116.
10. **Loeffler, J. M., D. Nelson, and V. A. Fischetti.** 2001. Rapid killing of *Streptococcus pneumoniae* with a bacteriophage cell wall hydrolase. Science **294:**2170–2172.
11. **Loessner, M. J.** 2005. Bacteriophage endolysins—current state of research and applications. Curr. Opin. Microbiol. **8:**480–487.
12. **Lopez, R., and E. Garcia.** 2004. Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage. FEMS Microbiol. Rev. **28:**553–580.
13. **Mokrasch, L. C.** 1967. Use of 2,4,6-trinitrobenzenesulfonic acid for the coestimation of amines, amino acids and proteins in mixtures. Anal. Biochem. **18:**64–71.
14. **Nelson, D., L. Loomis, and V. A. Fischetti.** 2001. Prevention and elimination of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. USA **98:**4107–4112.
15. **Pritchard, D. G., S. Dong, J. R. Baker, and J. A. Engler.** 2004. The bifunctional peptidoglycan lysin of *Streptococcus agalactiae* bacteriophage B30. Microbiology **150:**2079–2087.
16. **Schuch, R., D. Nelson, and V. A. Fischetti.** 2002. A bacteriolytic agent that detects and kills *Bacillus anthracis*. Nature **418:**884–889.
17. **Sehgal, D., and I. K. Vijay.** 1994. A method for the high efficiency of water-soluble carbodiimide-mediated amidation. Anal. Biochem. **218:**87–91.
18. **Sheehan, M. M., J. L. Garcia, R. Lopez, and P. Garcia.** 1996. Analysis of the catalytic domain of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling. FEMS Microbiol. Lett. **140:**23–28.
19. **Tettelin, H., V. Masignani, M. J. Cieslewicz, J. A. Eisen, S. Peterson, M. R. Wessels, I. T. Paulsen, K. E. Nelson, I. Margarit, T. D. Read, L. C. Madoff, A. M. Wolf, M. J. Beanan, L. M. Brinkac, S. C. Daugherty, R. T. DeBoy, A. S. Durkin, J. F. Kolonay, R. Madupu, M. R. Lewis, D. Radune, N. B. Fedorova, D. Scanlan, H. Khouri, S. Mulligan, H. A. Carty, R. T. Cline, S. E. Van Aken, J. Gill, M. Scarselli, M. Mora, E. T. Iacobini, C. Brettoni, G. Galli, M. Mariani, F. Vegni, D. Maione, D. Rinaudo, R. Rappuoli, J. L. Telford, D. L. Kasper, G. Grandi, and C. M. Fraser.** 2002. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V *Streptococcus agalactiae*. Proc. Natl. Acad. Sci. USA **99:**12391–12396.
20. **Vollmer, W., and A. Tomasz.** 2002. Peptidoglycan *N*-acetylglucosamine deacetylase, a putative virulence factor in *Streptococcus pneumoniae*. Infect. Immun. **70:**7176–7178.